SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-027951
Filing Date
2020-09-23
Accepted
2020-09-23 09:08:40
Documents
9
Period of Report
2020-09-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea127215-8k_protarathera.htm 8-K 48651
2 UNDERWRITING AGREEMENT RELATED TO THE COMMON OFFERING, DATED SEPTEMBER 22, 2020, ea127215ex1-1_protara.htm EX-1.1 249450
3 UNDERWRITING AGREEMENT RELATED TO THE PREFERRED OFFERING, DATED SEPTEMBER 22, 20 ea127215ex1-2_protara.htm EX-1.2 245822
4 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHT ea127215ex3-1_protara.htm EX-3.1 13272
5 OPINION OF COOLEY LLP ea127215ex5-1_protara.htm EX-5.1 16120
6 PRESS RELEASE, DATED SEPTEMBER 21, 2020 ea127215ex99-1_protara.htm EX-99.1 13559
7 PRESS RELEASE, DATED SEPTEMBER 22, 2020 ea127215ex99-2_protara.htm EX-99.2 14275
8 GRAPHIC ex5-1_001.jpg GRAPHIC 7474
9 GRAPHIC image_001.jpg GRAPHIC 3732
  Complete submission text file 0001213900-20-027951.txt   618279
Mailing Address 1 LITTLE WEST 12TH STREET NEW YORK NY 10014
Business Address 1 LITTLE WEST 12TH STREET NEW YORK NY 10014 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 201191059
SIC: 2836 Biological Products, (No Diagnostic Substances)